OPTN Stock Overview
A specialty pharmaceutical company, focuses on the development and commercialization of products for patients treated by ear, nose, throat, and allergy specialists in the United States.
| Snowflake Score | |
|---|---|
| Valuation | 5/6 |
| Future Growth | 5/6 |
| Past Performance | 0/6 |
| Financial Health | 1/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
OptiNose, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$1.16 |
| 52 Week High | US$2.10 |
| 52 Week Low | US$0.80 |
| Beta | -0.10 |
| 1 Month Change | 12.62% |
| 3 Month Change | -21.09% |
| 1 Year Change | -14.07% |
| 3 Year Change | -63.64% |
| 5 Year Change | -85.73% |
| Change since IPO | -93.89% |
Recent News & Updates
Recent updates
Not Many Are Piling Into OptiNose, Inc. (NASDAQ:OPTN) Stock Yet As It Plummets 42%
Apr 27
There's Reason For Concern Over OptiNose, Inc.'s (NASDAQ:OPTN) Massive 32% Price Jump
Mar 01Revenues Working Against OptiNose, Inc.'s (NASDAQ:OPTN) Share Price
Dec 28OptiNose, Inc. (NASDAQ:OPTN) Might Not Be As Mispriced As It Looks After Plunging 29%
May 23The Consensus EPS Estimates For OptiNose, Inc. (NASDAQ:OPTN) Just Fell Dramatically
Mar 09OptiNose GAAP EPS of -$0.23 beats by $0.01, revenue of $20.6M misses by $0.9M
Aug 11OptiNose: Potential Winner In Chronic Sinusitis Treatment
Jun 16OptiNose: Underappreciated Potential
Mar 10OptiNose: Undiscovered Gem
Aug 31OptiNose: Growing Sales Make The Current Market Cap Look Very Low
Jul 19OptiNose, Inc. 2021 Q1 - Results - Earnings Call Presentation
May 09OptiNose EPS beats by $0.03, beats on revenue
May 05OptiNose's Business Is Thriving While OptiNose Trades At Lower Revenue Multiples Than Peers
Dec 01OptiNose EPS beats by $0.06, beats on revenue
Nov 05Shareholder Returns
| OPTN | US Pharmaceuticals | US Market | |
|---|---|---|---|
| 7D | -2.1% | 1.9% | 1.2% |
| 1Y | -14.1% | 16.7% | 27.7% |
Return vs Industry: OPTN underperformed the US Pharmaceuticals industry which returned 16.7% over the past year.
Return vs Market: OPTN underperformed the US Market which returned 27.7% over the past year.
Price Volatility
| OPTN volatility | |
|---|---|
| OPTN Average Weekly Movement | 13.4% |
| Pharmaceuticals Industry Average Movement | 9.8% |
| Market Average Movement | 5.9% |
| 10% most volatile stocks in US Market | 16.2% |
| 10% least volatile stocks in US Market | 2.8% |
Stable Share Price: OPTN's share price has been volatile over the past 3 months.
Volatility Over Time: OPTN's weekly volatility (13%) has been stable over the past year, but is still higher than 75% of US stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2000 | 132 | Ramy Mahmoud | www.optinose.com |
OptiNose, Inc., a specialty pharmaceutical company, focuses on the development and commercialization of products for patients treated by ear, nose, throat, and allergy specialists in the United States. The company offers XHANCE, a therapeutic product utilizing its proprietary exhalation delivery system (EDS) that delivers a topically acting corticosteroid for the treatment of chronic rhinosinusitis with nasal polyps, as well as is in Phase IIIb clinical trial for treatment of chronic sinusitis; and Onzetra Xsail, a powder EDS device. It has a license agreement with Currax Pharmaceuticals LLC for the commercialization of Onzetra Xsail.
OptiNose, Inc. Fundamentals Summary
| OPTN fundamental statistics | |
|---|---|
| Market cap | US$168.01m |
| Earnings (TTM) | -US$30.70m |
| Revenue (TTM) | US$74.02m |
2.3x
P/S Ratio-5.5x
P/E RatioIs OPTN overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| OPTN income statement (TTM) | |
|---|---|
| Revenue | US$74.02m |
| Cost of Revenue | US$8.16m |
| Gross Profit | US$65.86m |
| Other Expenses | US$96.57m |
| Earnings | -US$30.70m |
Last Reported Earnings
Mar 31, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.21 |
| Gross Margin | 88.98% |
| Net Profit Margin | -41.48% |
| Debt/Equity Ratio | -131.7% |
How did OPTN perform over the long term?
See historical performance and comparison